InterveneRx is launching its innovative InterV CM+ platform with Allied National, Inc. in a first of its kind care management program for specialty drug patients. InterV CM+ integrates evidenced based protocols with biometric devices and a mobile application for real-time clinical monitoring of patients. Over 50 patients across 19 states will be monitored for improvements in clinical outcomes, utilization and patient engagement.
In partnership with UMass Medical School, InterveneRx will also integrate a clinically enhanced specialty drug prior authorization process during this phase to evaluate its impact on the efficiency and appropriateness of specialty drug approvals.
“We pride ourselves on delivering innovation and best value for our clients, and the results of the InterveneRx program launch will provide us with real outcomes for our clients’ specialty drug patients,” stated Bill Ashley, CEO of Allied National., Inc.
“We believe the InterveneRx platform fills a significant gap in determining the clinical value and effectiveness of specialty drugs. We are pleased that such a forward thinking company as Allied National, Inc. will be implementing this platform to monitor and manage their specialty drug patients,” said IntereveneRx CEO Mark Steck, Pharm D, MBA.
Allied National, Inc. expects to roll the program out to all of its clients nationwide by Q4 2017.